Authors

The Competitive Edge in Pharma Logistics: Sustainability, Safety, and Precision Delivery

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Beyond Awareness: Modeling Shared Decision-Making in Patient Communications

When patients struggle to see a positive path forward, modeling a constructive journey can give them the confidence they need.

Impact, Access, and Scale: The Potential of India’s Pharma Market

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

AI in Drug Discovery On-Demand Webinar

Revolutionizing Pharma Patient Assistance Programs, KnippeRx Leads the Future of Patient Care

Impact, Access, and Scale: The Potential of India’s Pharma Market

Country is poised to offer growth-channel opportunities for global pharma companies ready to scale access, innovation, and profitability.

The Shifting Pharmacy Landscape in 2025

Polypharmacy, biosimilars, and GLP-1s among the evolving trends likely to play out in the pharmacy benefits space.

The Ways Pharma Leaders are Rewiring their Organizations for Launch Success

Going Beyond Compliance: Early Adoption of FDA’s Quality Management Maturity Program—and the Practical Considerations for Executives

An examination of proactive preparedness and readiness review for future enrollment in the agency’s QMM program—now in the pilot stage as an effort to incentivize pharma manufacturers to achieve a more mature state of quality culture.

Rethinking Audience Modeling: AI, Regulations, & More

The intersection of artificial intelligence and direct-to-consumer advertising presents unprecedented opportunities and evolving challenges as regulations and technologies reshape the biopharma landscape.

How AI is Shaping KOL and DOL Identification

As drugmakers navigate an increasingly complex terrain of scientific and digital influence, the ability to accurately identify and understand both key and digital opinion leaders is vital for effective engagement.

HEOR: From Proving Product Value to Proving Its Own Worth

The recent shift in Health Economics and Outcomes Research functions across major pharmaceutical companies highlights a lack of understanding of its value.

Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations

As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.

Beyond the Data: Making HCP Analytics Actually Work for Commercial Teams

Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at scale while managing large territories and diverse customer bases.

How Does the Shift to Early-Stage M&A Change Due Diligence?

A well-defined scientific and strategic approach is critical for buyers in this dealmaking setting.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Making an Impact in the Era of Disinformation

With increasing cases of disinformation across social media blurring the lines of what’s credible and real, how can pharma break through the noise and build back public trust?

China’s Trial Advantage: Tracking Nation’s Growth in Pharma Innovation and Global Investment

A look at China's emergence as a hub for novel treatment pursuits—and ways international investors can best capitalize on the favorable research trajectory.

Powering Pipelines Forward: Approach Science Differently

Why tapping the value generated for the next set of therapies is critical.

Exploring Biopharma's Dealmaking Terrain, Roadmap in China

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

Mission-Critical Freight: Meeting the Rising Demands of High-Stakes Industries

This eBook explores Werner Enterprises' specialized logistics for high-stakes industries like healthcare, pharmaceuticals and high-end technology. It details how the company ensures the security and integrity of sensitive shipments through real-time tracking, rigorous driver training and advanced temperature control.

'Discovery to Delivery': How BPD Buy Helps MJH Bridge Science of Discovery With The Systems That Deliver Care

In this video discussion with Pharmaceutical Executive, Michael J. Hennessy Jr., chairman and CEO of MJH Life Sciences, and Jason Brown, CEO of BPD Healthcare, discuss how the deal came together and what it means for healthcare executives navigating an increasingly complex marketplace.

Transforming Healthcare: Beyond Buzzwords to Purposeful Change

For a growth mindset to truly take hold, leaders must create space for those possibilities to thrive.

Final Thoughts

The future of CAR T-cell therapies will continue to improve as they expand to other patients in need.

Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech

Ken Banta and Andrew Hall share insights on leading through uncertainty—covering culture, capital, risk, and the regulatory headwinds influencing key decisions in drug development.

Using AI to Predict Launch Success

How to maximize market-entry performance for new pharma products in an increasingly competitive launch environment.

In Obesity Care, NPs and PAs Are the Influencers Marketers Can’t Ignore

The booming obesity drug market is redefining prescriber influence, with nurse practitioners and physician associates emerging as key decision-makers that life sciences marketers can no longer afford to overlook.